A Randomised, Double-Blind, Intra-Individual Controlled, Single-Center, Phase I Dose Escalation Healthy Volunteer Study to Determine the Safety and Tolerability of MT10109 (Clostridium Botulinum Toxin Type A) in Comparison to Botox(Registered Trademark).
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2016
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Blepharospasm; Equinus foot deformity; Glabellar lines; Hypertrophy; Muscle spasticity; Spasm; Torticollis
- Focus Adverse reactions
- Sponsors Medytox
- 06 Dec 2011 Status changed from recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
- 27 Jan 2011 New trial record